A TAVR deal would be much better once we have initial results of our TAVR safely in man. However, there are other options for a tissue deal which could bring in revenue. The market is seemly discounting this option to zero chance.
As an example our tissue is FDA approved and with an FDA clearance could probably be used in an existing TAVR device while DurAVR progresses through its regulatory process.
There is also the big opportunity in CABG that could be licenced. It’s not like we have been unable to do good licensing deals before considering what we did with LeMatre that validated big company interest in our science and products.
While a CR could still be a possibility it is not a foregone conclusion.
A TAVR deal would be much better once we have initial results of...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.71 |
Change
0.010(0.06%) |
Mkt cap ! $301.9M | |||
| Open | High | Low | Value | Volume |
| $16.00 | $16.01 | $15.49 | $3.254M | 230.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $15.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.20 | 700 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |